Boston, MA -- (SBWIRE) -- 10/09/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: Peregrine Pharmaceuticals (NASDAQ:PPHM), Merck & Co., Inc. (NYSE:MRK),Janus Capital Group Inc (NYSE:JNS), Cellceutix Corp (OTCMKTS:CTIX).
Peregrine Pharmaceuticals (NASDAQ:PPHM) opened its shares at the price of $1.46for the day. Its closing price was $1.39 after losing -4.14% for the day. The company traded with the total volume of 1.74 million shares, while its average trading volume remained 1.08 million shares. The beta of PPHM stands at1.02.
Will PPHM Get Buyers Even After The Recent Rally? Find Out Here
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. Merck & Co., Inc. (NYSE:MRK) percentage change plunged -0.29% to close at $47.75 with the total traded volume of 14.02 million shares, and average volume of 14.03 million. The 52 week range of the stock remained $40.02 - $50.16, while its day lowest price was $47.64and it hit its day highest price at $48.15.
Will MRK Get Buyers Even After The Recent Rally? Find Out Here
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Janus Capital Group Inc (NYSE:JNS) started its trading session with the price of $8.77 and closed at $8.56 by scoring -2.17%. JNS’s stocks traded with total volume of 4.87 million shares, while the average trading volume remained 2.20 million shares. The beta of JNS stands at 2.74. Day range of the stock was $8.55 -$9.06.
Will JNS Get Buyers Even After The Recent Rally? Find Out Here
Janus Capital Group Inc., and its subsidiaries (JCG) provide investment management, administration, distribution and related services to financial advisors, individuals and institutional clients through mutual funds, other pooled investment vehicles, separate accounts and sub advised relationships (collectively referred to as investment products) in both domestic and international markets. Cellceutix Corp (OTCMKTS:CTIX) ended its day with the loss of -4.52% and closed at the price of $1.69 after opening at $1.78. Stock traded during its last trading session with the total volume of 265,578 shares, as compared to its average volume of 325,101 shares.
Will CTIX Get Buyers Even After The Recent Rally? Find Out Here
Cellceutix Corporation is an early-stage developmental biopharmaceutical company. The Company has acquired exclusive rights to eight different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or may exist in the future.
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/ and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)